Maximising the public health benefit of antimalarials

The Lancet Infectious Diseases

Volumn 10, Issue 10, 2010, Pages 654-655

  Price, Ric N ^a,b   Douglas, Nicholas M ^a  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE; ARTEMISIN; ARTEMISININ DERIVATIVE; LACTONE;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG EFFICACY; GAMETOCYTE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOLYSIS; HUMAN; LETTER; MALARIA FALCIPARUM; MIXED INFECTION; PARASITE CONTROL; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; DRUG COMBINATION; DRUG EFFECTS; MALARIA; PLASMODIUM; PROCEDURES;

ANTIMALARIALS; ARTEMISININS; DRUG THERAPY, COMBINATION; HUMANS; LACTONES; MALARIA; PLASMODIUM;

EID: 77957141394     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(10)70192-4     Document Type: Letter

References (12)

1. Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010, published online Sept 9. 10.1016/S1473-3099(10)70187-0.
2. Ratcliff A, Siswantoro H, Kenangalem E, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007, 369:757-765.
3. Hastings IM, Watkins WM Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol 2006, 22:71-77.
4. Stepniewska K, Price RN, Sutherland CJ, et al. Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malar J 2008, 7:249.
5. Smithuis F, Kyaw MK, Phe O, et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 2006, 367:2075-2085.
6. Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 2009, 4:e7871.
7. Valecha N, Phyo AP, Mayxay M, et al. An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One 2010, 5:e11880.
8. Shekalaghe S, Drakeley C, Gosling R, et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One 2007, 2:e1023.
9. Shekalaghe SA, ter Braak R, Daou M, et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother 2010, 54:1762-1768.
10. Looareesuwan S, White NJ, Chittamas S, Bunnag D, Harinasuta T High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet 1987, 2:1052-1055.
11. Mason DP, Krudsood S, Wilairatana P, et al. Can treatment of P vivax lead to a unexpected appearance of falciparum malaria?. Southeast Asian J Trop Med Public Health 2001, 32:57-63.
12. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010, 10:405-416.